Shanghai Junshi Biosciences’ Toripalimab Gains NMPA Nod for First-Line TNBC Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that it has received...
Harbour BioMed Resubmits Biological License Application for Batoclimab in China
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands,...
Shanghai’s Phrontline Biopharma Secures Over RMB 100 Million in Pre-Series A Funding for ADC Development
Shanghai-based antibody drug conjugate (ADC) specialist Phrontline Biopharma has reportedly secured over RMB 100 million...
Antengene’s Xpovio Included in South Korea’s NHIS Reimbursement Drug List
Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced that South...
Bio-Thera Solutions’ BAT1806 Biosimilar Receives European Commission Approval
Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it...
Revvity and Sanyou Biopharmaceuticals Deepen Partnership to Advance Biologic Drug Development
Shanghai-based biotechnology company Revvity has entered into a comprehensive partnership with Sanyou Biopharmaceuticals Co., Ltd...
Novartis’s Scemblix STAMP Inhibitor for CML Accepted for Review by China’s NMPA
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has had its market filing for Scemblix (asciminib)...
Novo Nordisk’s Ocedurenone Misses Primary Endpoint in Chronic Kidney Disease Trial
Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a Danish pharmaceutical company, has announced that its pipeline...
Merck’s HER3-Targeted ADC Patritumab Deruxtecan Faces FDA Complete Response Letter
Merck, Sharp & Dohme Inc. (NYSE: MRK), a leading U.S. pharmaceutical company, has announced that...
Moderna’s RSV Vaccine Efficacy Wanes to 50% After 18 Months, Shares Slide
Moderna Inc. (NASDAQ: MRNA), a U.S.-based biopharmaceutical company, has announced long-term efficacy data for its...
CASI Pharmaceuticals Secures USD 15 Million in PIPE Transaction for Anti-CD38 Monoclonal Antibody Development
CASI Pharmaceuticals (NASDAQ: CASI), a biopharmaceutical company based in China, has announced the signing of...
J&J Halts Mid-Stage Trial for Tremfya in Giant Cell Arteritis Due to Efficacy Concerns
Johnson & Johnson (J&J; NYSE: JNJ), a leading U.S.-based healthcare company, has reportedly discontinued a...
AstraZeneca’s Tagrisso Wins NMPA Approval for First-Line EGFR-mutated NSCLC Treatment
AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical company, has announced that it has received another...
Sanofi Invites Bids Starting at $20 Billion for Consumer Health Unit
Sanofi (NYSE: SNY) is reportedly inviting bids starting at USD 20 billion for its consumer...
China’s NMPA Proposes Expedited Review for Clinically Urgent Overseas Drugs
The National Medical Products Administration (NMPA) has released a draft proposal titled “Announcement of the...
Eli Lilly & Co. Partners with OpenAI to Use Generative AI in Antimicrobial Drug Discovery
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the U.S., has...
Aidea Pharmaceutical to Boost Stake in Nanda Pharmaceutical to 51.1256%
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a pharmaceutical company based in China, is poised...
Sino Biopharmaceutical Gains NMPA Approval for Liraglutide Biosimilar for Type 2 Diabetes
Sino Biopharmaceutical Ltd (HKG: 1177), a major player in China’s pharmaceutical industry, has announced that...
CSPC Pharmaceutical’s BCMA-Targeted CAR-T Therapy SYS6020 Receives NMPA Clinical Trial Approval
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...
Novo Nordisk’s Semaglutide for Long-Term Weight Management Receives NMPA Approval
Novo Nordisk (NYSE: NVO, CPH: NOVO-B), a leading healthcare company from Denmark, has announced that...